STOCKSCOPE

Noble Helium (ASX: NHE): $3.9 Million in Cash, a Major Helium Drilling Campaign and a Critical Funding Test

Alison Elzayed

Alison Elzayed

Business & Finance Writer | StockScope

Published:5d ago
Noble Helium (ASX: NHE): $3.9 Million in Cash, a Major Helium Drilling Campaign and a Critical Funding Test

Noble Helium Limited (ASX: NHE) is approaching a defining stage in its exploration strategy, with its Kinambo helium drilling programme in Tanzania advancing towards a critical operational milestone and a major Australian expansion creating additional exploration opportunities.

However, the company's September quarterly results reveal a significant financial challenge. Cash reserves have fallen to $3.9 million, while exploration expenditure continues ahead of commercial production.

The central question is whether Noble can demonstrate commercially recoverable helium resources before further funding becomes necessary.

Key numbers

  • $3.905 million: Cash reserves at 30 September 2026.
  • $2.431 million: Combined quarterly operating and exploration cash outflows.
  • 1.61 quarters: Estimated funding runway based on September quarter expenditure.
  • $4.91 million: FY2026 net loss, compared with $10.97 million in FY2025.
  • 40,000-plus square kilometres: Australian exploration acreage associated with the Earth Source Hydrogen acquisition.

Kinambo drilling could determine Noble's commercial future

Noble's immediate priority remains its North Rukwa helium project in Tanzania, where the company is targeting helium resources capable of supporting future commercial production.

During the September quarter, Noble completed access roads, well pads and accommodation facilities for its Kinambo drilling campaign.

The company appointed SLB to provide wireline logging and downhole sampling services, which will help establish the characteristics and potential recoverability of helium within the targeted structures.

However, mobilisation of BoreXpert's drilling rig was paused following delays involving SLB's commitments to another project.

Although this has disrupted the drilling timetable, Noble has used the interruption to refine operational planning and reduce weather-related risks.

The key commercial objective remains demonstrating whether shallow helium-bearing formations can support a lower-capital-cost production development.

Successful drilling could strengthen Noble's development strategy, but helium concentrations, recoverable volumes, flow characteristics and production economics remain unproven.

Australian expansion adds scale but also execution demands

Noble completed its acquisition of Earth Source Hydrogen on 30 September 2026, significantly expanding its exposure to naturally occurring hydrogen and helium in Western Australia.

The transaction included three Special Prospecting Authorities covering more than 40,000 square kilometres, providing exclusive rights to apply for exploration licences rather than immediate production rights.

On 19 October, Noble lodged an exploration permit application covering approximately 7,760 square kilometres at Merlinleigh.

Elevated helium and hydrogen measurements identified through groundwater sampling provide encouragement for further investigation, although they do not establish commercially recoverable resources.

The acquisition consideration included approximately 87.2 million shares, with around 11.3 million subject to shareholder approval.

David Biggs also became Executive Director on 16 October, strengthening the company's leadership during its expanded exploration programme.

While diversification creates additional geological opportunities, the transaction increases the number of projects competing for exploration capital.

Cash reserves expose the next major funding challenge

Noble's financial position remains a central concern.

Cash declined from $6.689 million at 30 June to $3.905 million at 30 September 2026.

Quarterly operating cash outflows totalled $549,000, while exploration and evaluation expenditure reached $1.882 million.

Together, these expenditures produced an estimated funding runway of just 1.61 quarters, assuming spending continues at the September quarter rate.

The FY2026 net loss narrowed approximately 55% from the previous year, although the comparison was influenced by substantial earlier charges, including disputed drilling costs and a doubtful-debt provision.

More importantly, the FY2026 auditor highlighted a material uncertainty regarding Noble's ability to continue as a going concern.

Management has indicated confidence in securing additional capital if required, following approximately $12 million raised before costs during FY2026. However, further funding is not guaranteed.

For shareholders, the critical issue is whether future exploration success can justify additional capital commitments without excessive dilution.

Conventional earnings-based valuation measures remain unsuitable because Noble has no meaningful commercial helium revenue.

Insight: Can Kinambo deliver results before funding pressure intensifies?

What stands out to us is the contrast between Noble's expanding exploration portfolio and its limited financial flexibility. More than 40,000 square kilometres of additional Australian acreage creates long-term geological potential, but Kinambo remains the more immediate test of commercial value. We see a credible opportunity if drilling establishes recoverable helium volumes capable of supporting economically viable production. However, additional capital requirements could offset some of that progress. The next decisive evidence will be independently assessed helium concentrations, recoverable volumes and preliminary development economics.

The verdict: Exploration progress must become commercial evidence

Noble Helium has strengthened its exploration portfolio and completed important preparations for its Tanzanian drilling programme, but commercial viability remains unproven.

The opportunity is potentially meaningful, particularly if Kinambo supports a lower-capital-cost helium development.

However, drilling delays, limited funding runway and the auditor's going-concern warning demand caution.

The next Kinambo drilling update, independent resource assessment and quarterly cash-flow report will determine whether Noble is moving closer to a financeable helium project or another capital-intensive exploration phase.

Alison Elzayed

Alison Elzayed

(Business & Finance Writer | StockScope)

Alison Elzayed is an experienced business and financial writer with more than 10 years of experience in the publishing industry, having previously worked as an author with Bloomsbury Publishing, specialising in business and finance. Throughout her career, Alison has developed a strong understanding of financial markets, corporate developments, economic trends and investment-related topics. Her background in financial publishing has equipped her with the ability to research complex subjects and communicate them in a clear, accurate and engaging manner.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet
Mining
Mining

Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet

Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...

Alison ElzayedAlison Elzayed•
Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?
Biotech & Health
Biotech & Health

Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...

Danny AadDanny Aad•
Loading more stories...